14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABOS vs DOOO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DOOO Overall Winner
6-Pillar Tally: ABOS 1 – 5 DOOO
Matrix Metrics: ABOS 1 – 9 DOOO
As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABOS carries a Unified Composite Score of 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin), whereas DOOO carries 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin).
Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4); meanwhile DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs DOOO. Trailing 12-month operating profitability (ABOS 0.0% vs DOOO 4.8%) and valuation multiples (ABOS N/M vs DOOO 14.4x Forward P/E) are benchmarked directly in Pillar 4 below.
ABOS Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $14.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DOOO Moat ProfileHigh-Margin Pricing Power Moat
Miscellaneous Transportation Equipment Operator
Competes within the Miscellaneous Transportation Equipment value chain with $5.1B market capitalization and 4.8% operating margin.
OpEx & R&D Reinvestment16.4% of Rev ($1.27B)
90D Engineering Disclosures0 Published
Investor FAQ ABOS vs DOOO Key Questions & Quantitative Answers
As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABOS carries a Unified Composite Score of 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin), whereas DOOO carries 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin). Technical & Structure Timing Caution: ABOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4); meanwhile DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DOOO leads the Growth & Scale pillar: ABOS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with DOOO at +4.3% YoY revenue growth and +295.8% YoY earnings growth on $7.75B TTM revenue (21.2% gross margin, 4.8% operating margin). On trailing 12-month operating scale, ABOS generates $329,000 in USD-normalized revenue versus $7.75B for DOOO. In operating R&D and SG&A reinvestment, ABOS deploys N/A (0 90-day corporate R&D disclosures) versus 16.4% of Rev ($1.27B) (0 disclosures) for DOOO.
DOOO screens cheaper on headline valuation multiples. ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas DOOO trades at 14.4x Forward P/E, 36.1x Trailing P/E, 2.04x PEG, and 0.7x EV/Revenue (10.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABOS (-162.7% ROE) versus DOOO (37.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.62β · 326% Vol realized risk). By comparison, DOOO carries 42.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 39% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.